Evidence map›Paper›PMID 27446451›Full record

ArticleOncology letters2016

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

Liyu Jiang, Chuyu Jing, Xiaoli Kong, Xiaoyan Li, Tingting Ma, Qiang Huo, Junfei Chen, Xiaoting Wang, Qifeng Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Liyu JiangDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Chuyu JingDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Xiaoli KongDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Xiaoyan LiDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Tingting MaDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Qiang HuoDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Junfei ChenDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Xiaoting WangDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Qifeng YangDepartment of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China; Pathology Tissue Bank, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In China, the adjuvant epirubicin and docetaxel (ED) regimen is widely used as a substitute for the epirubicin and cyclophosphamide followed by docetaxel (EC-D) regimen in patients with operable breast cancer. However, their equivalence has not yet been demonstrated. This retrospective study compared these two adjuvant regimens as regards feasibility, safety and efficacy. Data on consecutive patients who received either ED (70/75 mg/m

Indexed as

adjuvant chemotherapybreast cancerdocetaxelepirubicinprognosis

Identifiers

PMID27446451
PMCPMC4950445
OpenAlexW2468395122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.